
0人評分過此書
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: ‧ Epidemiology, pathophysiology and etiology ‧ Diagnosis ‧ Treatment ‧ Supportive care ‧ Prognosis and monitoring ‧ Emerging treatments ‧ Useful resources
- Cover
- Title Page
- Copyright
- Contents
- List of abbreviations
- Introduction
-
Epidemiology, pathophysiology and etiology
-
Epidemiology
-
Pathophysiology
-
The role of genetics
-
Etiology
-
-
Diagnosis
-
Clinical presentation
-
Differential diagnosis
-
Pretreatment evaluation
-
Classification
-
-
Treatment
-
Standard treatment
-
Standard induction chemotherapy
-
Newly approved drugs
-
Standard consolidation therapy (following intensive induction)
-
Treatment selection
-
Induction in older and physically ‘unfit’ patients
-
Treatment of relapsed and refractory disease
-
New treatment options for patients with relapsed or refractory disease
-
Treatment of acute promyelocytic leukemia
-
-
Supportive care
-
Other supportive measures
-
-
Prognosis and monitoring
-
Age
-
Comorbidities
-
Cytogenetic and molecular signatures
-
Measurable residual disease monitoring
-
-
Research directions
-
Drugs in late-stage development
-
Novel immunotherapies
-
A new era for clinical trials in AML?
-
- Useful resources
- Index
- 出版地 : 德國
- 語言 : 德文
評分與評論
請登入後再留言與評分